Evidence map›Paper›PMID 42500735›Full record

ReviewPharmaceutical science advances2026

Recent advances in the bioanalysis of acylcarnitines: Methodologies, challenges, and clinical perspectives.

Jiaxin Zheng, Wanting Chen, Fengxia Qin, Pei Zhang, Fengguo Xu

Abstract readReview
In one paragraph

Review in Pharmaceutical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiaxin ZhengAffiliated Jiangning Chinese Medicine Hospital, China Pharmaceutical University, Nanjing, 211100, PR China.
Wanting ChenAffiliated Jiangning Chinese Medicine Hospital, China Pharmaceutical University, Nanjing, 211100, PR China.
Fengxia QinAffiliated Jiangning Chinese Medicine Hospital, China Pharmaceutical University, Nanjing, 211100, PR China.
Pei ZhangAffiliated Jiangning Chinese Medicine Hospital, China Pharmaceutical University, Nanjing, 211100, PR China.
Fengguo XuAffiliated Jiangning Chinese Medicine Hospital, China Pharmaceutical University, Nanjing, 211100, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acylcarnitines (ACs) are a diverse class of fatty acid esters of L-carnitine that serve as critical mediators in energy homeostasis and mitochondrial function. Beyond their classical role in newborn screening for inborn errors of metabolism, ACs have emerged as promising biomarkers for complex pathologies, including cardiovascular diseases, diabetes, and drug-induced toxicities. However, the accurate quantification and comprehensive profiling of ACs in biological matrices remain analytically challenging due to their broad polarity range, vast concentration disparities, and the presence of isomers. This review provides a comprehensive overview of the current bioanalytical strategies for ACs, covering sample preparation techniques and detection platforms, with a focus on liquid chromatography-mass spectrometry. Special attention is given to the differentiation of isomers. Finally, we discuss the clinical applications of ACs profiling and highlight future perspectives, including the integration of ion mobility spectrometry, automated high-throughput workflows, spatial and single-cell metabolomics, and AI-driven analytics, to pave the way for precision medicine.

Indexed as

AcylcarnitinesClinical diagnosisMass spectrometryMetabolic diseaseSample pretreatment

Identifiers

PMID42500735
PMCPMC13396923

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.